Pediatrix Medical (MD): Growing Demand for Neonatal CarePediatrix Medical Group, Inc. (MD) is a healthcare company specializing in neonatal, maternal-fetal, and pediatric care. It provides expert medical services to hospitals and healthcare systems, focusing on high-risk pregnancies, newborn care, and pediatric specialties. With a growing need for specialized healthcare, Pediatrix continues expanding its network of providers and services, ensuring quality care for patients and long-term stability for the company.
The stock chart recently showed a confirmation bar with increasing volume, moving into the momentum zone, which happens when the price moves above the 0.236 Fibonacci level. This signals strong investor confidence and potential for further gains as buyers step in.
Using a trailing stop is an effective way to manage risk while securing profits. By setting a trailing stop based on Fibonacci levels, traders can stay in a trade as long as the stock trends higher while locking in gains if momentum slows. This strategy prevents premature exits and ensures that profits are protected in case of a reversal.
MD trade ideas
Pediatrix Medical (MD): Pediatric Specialists Fuel GrowthPediatrix Medical Group, Inc. (MD) is a healthcare company specializing in neonatal, maternal-fetal, and pediatric care. It provides expert medical services to hospitals and healthcare systems, focusing on high-risk pregnancies, newborn care, and pediatric specialties. The company’s growth is driven by increasing demand for specialized healthcare and its expanding network of medical professionals across the U.S.
The stock chart recently showed a confirmation bar with increasing volume, moving into the momentum zone, which occurs when the price rises above the 0.236 Fibonacci level. This signals growing investor interest and potential for continued upside. Trailing stop losses can be set using Fibonacci levels with the Fibonacci snap tool, allowing traders to manage risk effectively while staying in the trend. This strategy helps protect potential gains while keeping the trade open for further upside.
Pediatrix Medical Group, Inc. | Chart & Forecast SummaryKey Indicators On Trade Set Up In General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Notes On Session
# Pediatrix Medical Group, Inc.
- Double Formation
* (Reversal Argument)) | Completed Survey
* 012345 | Wave Count Set Up | Subdivision 1
- Triple Formation
* (Uptrend Argument)) | Subdivision 2
* Numbered Retracement | Subdivision 3
* Daily Time Frame | Trend Settings Condition
Active Sessions On Relevant Range & Elemented Probabilities;
European Session(Upwards) - US-Session(Downwards) - Asian Session(Ranging)
Conclusion | Trade Plan Execution & Risk Management On Demand;
Overall Consensus | Buy
Pediatrix Medical Group, Inc. | Chart & Forecast SummaryKey Indicators On Trade Set Up In General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Notes On Session
# Pediatrix Medical Group, Inc.
- Double Formation
* 9.50 USD | Uptrend Bias | A+ Settings | Subdivision 1
* Pennant Structure | Survey Valid | Subdivision 2
- Triple Formation
* Retracement 1| Bias On hold | Entry Settings | Subdivision 3
* Retracement 2| ((50)) & 0.236)) | Hypothesis
* Retracement 3| 0.382)) & 1.618)) | Hypothesis
Active Sessions On Relevant Range & Elemented Probabilities;
London(Upwards) - NYC(Downwards)
Conclusion | Trade Plan Execution & Risk Management On Demand;
Overall Consensus | Neutral
New Setup: MDMD: I have a setup signal(green dot).I'm looking to enter long near the close of the day if the stock can manage to CLOSE above the last candle highs(white line). If triggered, I will then place a stop-loss below(SL) and a price target above it(TP-50%,move SL to breakeven), then using the close below the 10SMA as a trailing stop loss.
********
Note: The above setups will remain valid until the stock CLOSES BELOW my set stop-loss level(3).
Mednax outrageously oversold ahead of earningsIt's not every day you see a stock get this oversold on its weekly chart. Mednax, Inc. has lost about 50% of its value over the past year due to some earnings and revenue misses and year-over-year declines. After this drop, Mednax has a very attractive P/E of 8.66. Its forward P/E of 6.84 indicates that its earnings are expected to grow. S&P Capital IQ rates the company as highly undervalued.
Mednax has recently had some analyst upgrades, which could serve as an upward catalyst. Also, with an ESP of 2.13% from Zacks, Mednax may beat analyst estimates when it next reports earnings on August 1. MedData's revenue has grown over the last several earnings reports, and earnings misses have been mostly due to administrative and interest payment costs. An ongoing share buyback program has reduced the number of shares of common stock, which means the company's profit will be divided by fewer shares on the next report.
On the other hand, Mednax managed to miss both its own forecasts and the analysts' estimates on its last report, despite its buyback program. I don't see a lot of signs that Mednax has made progress toward cutting costs and improving margins since then. References to "restructuring" in past earnings reports are vague, but they probably refer to the so-far unsuccessful effort to sell the MedData division of the company. S&P Capital IQ rates the company as highly financially healthy, but I think that's an exaggeration. As best I can tell, the company has some pretty high-interest debt and is burning through its cash reserves. Employee reviews on Glassdoor suggest that top executives may not be providing competent leadership.
These concerns aside, Mednax's undervaluation and analyst ratings make it a potentially attractive buy ahead of earnings. Even a small earnings beat could give the stock a big bump. I see some bullish divergence on the chart that suggests a slowing of its downward momentum. I'll be watching closely for signs of positive investor sentiment, with an alert set to buy at the first sign of a breakout above the parallel channel.
MD breaks out on higher volumeMD was trending really well until early 2014 when there was a prolonged correction/pullback. Since then it has outperformed the S&P by some distance.
Price took it's time to comfortably clear the $64 zone, finally doing so on 29th January 2015 with an extremely large, bullish bar and higher volume. More recently, Friday's bar closed above the $70 round number (again on higher volume) so we should expect a continued move to the upside.
With earnings already announced, and a reasonably linear trend developing, MD offers a solid long opportunity.